Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danube Pharmaceuticals, a biopharmaceutical company specializing in the commercial R&D of drugs for ophthalmology, has appointed Barrett Katz as its new CEO.
Subscribe to our email newsletter
Prior to joining Danube, Dr Katz served as executive vice president and chief medical officer of Fovea Pharmaceuticals in Paris. Before that Dr Katz was vice president for medical affairs and medical strategy at Eyetech Pharmaceuticals.
David Guyer, chairman of Danube, said: “Dr Katz’s outstanding reputation in the international ophthalmology community coupled with his expertise in the field of drug development, drug approval and product launch will be invaluable for bringing Danube’s product candidates from clinical trials to market effectively and efficiently.”